Bicara Therapeutics Inc.
BCAX
$24.28
$0.652.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 96.37% | 70.92% | 20.40% | 61.65% | 84.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.24% | 44.16% | 54.38% | 97.19% | 62.12% |
| Operating Income | -87.24% | -44.16% | -54.38% | -97.19% | -62.12% |
| Income Before Tax | -102.57% | -52.71% | -79.74% | -107.60% | -60.34% |
| Income Tax Expenses | 17.31% | -27.78% | -71.51% | -- | -- |
| Earnings from Continuing Operations | -102.41% | -52.56% | -78.39% | -107.83% | -60.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.41% | -52.56% | -78.39% | -107.83% | -60.64% |
| EBIT | -87.24% | -44.16% | -54.38% | -97.19% | -62.12% |
| EBITDA | -87.22% | -44.12% | -54.30% | -97.22% | -62.13% |
| EPS Basic | -62.50% | -36.83% | -76.06% | 58.48% | 97.36% |
| Normalized Basic EPS | -62.62% | -36.96% | -77.40% | 58.52% | 97.36% |
| EPS Diluted | -62.50% | -36.83% | -76.06% | 58.48% | 97.36% |
| Normalized Diluted EPS | -62.62% | -36.96% | -77.40% | 58.52% | 97.36% |
| Average Basic Shares Outstanding | 24.55% | 11.50% | 1.32% | 400.54% | 5,982.21% |
| Average Diluted Shares Outstanding | 24.55% | 11.50% | 1.32% | 400.54% | 5,982.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |